Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0025202 (melanoma)
 69,561 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Of 65 patients with intrathoracic metastases from melanomon, 35 had metastasis to hilar or mediastinal nodes. In 28 of these 35, hilar and mediastinal lymph node enlargement was radiographically visible, hilar node enlargement was more commonly seen than mediastinal node enlargement. Pulmonary nodules were demonstrated radiographically in 25 of the 28 patients. Although lymph node enlargement was often asymmetric, symmetric hilar adenopathy mimicking sarcoidosis occurred in five of the 28 patients. Seven patients had unilateral involvement of lung and hilar and mediastinal nodes. In patients with melanoma, indirect metastatic spread via pulmonary nodules to hilar and mediastinal nodes may account for the frequent association of node metastases with lung nodules, the occurrence of intrathoracic adenopathy in the absence of extrathoracic node metastases, and the common finding of unilateral lung and nodal disease.
 ...
PMID:Hilar and mediastinal lymph node metastases in malignant melanoma. 11 64

After nodal metastasis from malignant melanoma, approximately 80% of patients die from disseminated disease. To clarify the role of radiation therapy (XRT) following node dissection. 56 patients with biopsy-proven nodal metastasis participated in a randomized, prospective clinical trial which compares radiation therapy to the regional lymph node area following lymphadenectomy (27 patients) with lymphadenectomy alone (29 patients). Interesting differences in the survival curves (p = 0.09) and in the disease-free interval curves (p = 0.08) for the two treatment groups proved to be attributable to imbalances in the age and nodal distributions in the treatment groups. Covariate analysis identified age and sex as the factors having the most significant (p less than 0.04) effect on survival and identified the number of positive nodes as the covariate having the most significant (p less than 0.02) effect on disease-free interval. Treatment did not have a significant effect upon survival or disease-free interval.
 ...
PMID:Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study. 36 55

Sixty patients with Stage II malignant melanoma were evaluated in order to compare preoperative gallium67 total body scan, physical examination findings, and ultimate histologic findings in regard to the site of the primary lesion and status of the regional lymph nodes. Physical examination was a more efficient and a more sensitive method of evaluation compared to gallium67 scanning in these patients when assessing nodal involvement.
 ...
PMID:Gallium67 scanning compared with physical examination in the preoperative staging of malignant melanoma. 47 63

To determine whether immediate or delayed lymphadenectomy is more beneficial than none in cases of localized (stage I) melanoma, we undertook in 1972 a prospective randomized study. Patients with midline trunk lesions were excluded as well as patients with lesions situated directly over the node-bearing area. In addition, because of the low risk of metastasis, the protocol was changed to exclude level 2 lesions. Of the 173 patients studied, 63 were randomized to no lymphadenectomy, 56 to delayed (3 months) lymphadenectomy, and 54 to immediate lymphadenectomy. None of these regimens differed significantly from the others in its effect on length of survival or interval to metastasis. And of the 110 patients who underwent elective lymphadenectomy, 103 were without nodal involvement. Our preliminary conclusion is that elective node dissection is not beneficial in management of melanoma. However, disease progression was advanced significantly by age of the patient (greater than 60 years) and by invasiveness (level 4 or 5) and thickness (greater than 1.5 mm) of the melanoma.
 ...
PMID:A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. 63 81

Colloidal gold radionucleotide 198Au scanning can demonstrate the direction of regional lymphatic drainage in patients with primary malignant melanoma. Each of 32 patients with primary melanoma of the trunk received an intradermal injection of 0.1 mCi of 198Au colloid around the primary melanoma site. Imaging was accomplished with a tomographic scanner 24 hours following the injection. Twenty-seven of these patients underwent 36 regional lymph node dissections; nine had nodal metastases histologically demonstrated in the area (s) of nucleotide uptake. In clinical evaluation of up to 55 weeks, no patients demonstrated regional lymph node metastases in node groups which did not show preoperative gold uptake. Early evidence shows excellent correlation between the route of regional lymph node metastases and the direction of lymphatic flow to regional node groups, as demonstrated by gold colloid scanning. This procedure may be useful for evaluating patients with histologically defined high risk melanomas situated on the trunk in areas which drain to one or more lymph node regions.
 ...
PMID:The determination of lymph shed by colloidal gold scanning in patients with malignant melanoma: a preliminary study. 71 78

Forty patients with disseminated malignant melanoma were treated with triple combination chemotherapy consisting of Imidazole Carboxamide, BCNU and Vincristine. Seventeen of 40 patients (42.5%) showed significant responses including three complete responses. Responses were seen in cutaneous, lymph node and pulmonary metastases. Nine instances of hepatic metastases were unaffected by therapy but 68% of the skin and nodal patients responded. The median response duration was only 4 months and the median survival of responders was 9.5 months compared to a 2 month median survival of non-responders. Half of the responders died of CNS metastases. The short duration of response, the resistance of hepatic metastasis and the high incidence of cerebral recurrence necessitate additional therapeutic approaches to this disease.
 ...
PMID:Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine. 83 50

Thirteen consecutive patients with inoperable recurrent malignant melanoma were treated by immunochemotherapy with the use of chlorambucil noncovalently bound to goat or rabbit antihuman melanoma globulins. The next consecutive 11 patients fulfilling the criteria for admission into this study were treated with chemotherapy only, i.e., dimethyltriazenoimidazole carboxamide (DTIC). Follow-up was for a minimum of 29 months or until death. Two patients showing an objective response to immunochemotherapy had disease confined to lymph nodes and cutaneous sites; 5 others showed stabilization of cutaneous, nodal, and visceral disease, and 6 patients showed progression of their disease. The median survival of the responders and stabilizers was 20 months, but only 3.5 months for patients with disease progression. None of the 11 patients treated with DTIC had objective tumor regression, and all died within 11 months of the start of treatment with a median survival of 3 months. Immunochemotherapy significantly prolonged the survival compared to that in the DTIC-treated group (P less than 0.05). No hematologic or renal toxicity was detected after immunochemotherapy, but 2 patients in this group developed anaphylactic reactions. Skin reactivity tests to dinitrochlorobenzene and purified protein derivative were of no prognostic value
 ...
PMID:Immunochemotherapy of malignant melanoma with chlorambucil-bound antimelanoma globulins: preliminary results in patients with disseminated disease. 84 89

During the years 1954 through 1964, 259 individuals with primary malignant melanoma had an elective node dissection. Microscopic metastases were found in 15% of these patients. The presence of only a microscopic focus of involvement gave a 10-year cure rate of 67%; metastasis larger than a microscopic focus in a single node, 50%; and more than one node, 15%. One hundred forty-five individuals were treated by wide excision alone with 18% subsequently requiring a therapeutic lymphadenectomy with a ten-year cure of only 6%. A prospective study was then initiated which was concerned with efficacy of selection of patients for elective node dissection. Clark's level of invasion was determined for 258 patients treated since January 1972. The depth of invasion of the primary lesion was found to correlate directly with the absence of lymph node metastases, extent of nodal involvement, and rate of recurrence. It is concluded that the concept of elective node dissection is valid.
 ...
PMID:Biostatistical basis of elective node dissection for malignant melanoma. 87 70

A clinicopathologic study was done in 151 patients with malignant melanoma of the extremities who were surgically treated in Memorial Hospital and had 5-to 9-year followup. Microstaging was done according to the depth of invasion, as determined by Clark's levels as well as by direct measurement. This was related to treatment and to clinical course. There was a correlation between the depth of invasion by Clark's levels and the incidence of lymph node metastases in patients with Stage I melanoma who had elective node dissection. The incidence of nodal metastases was 4% for Level II, 7% FOR Level III, 25% for Level IV, and 70% for Level V. There was a correlation between Clark's level of invasion and survival aftter surgery. The 5-year cure rate was 100% for Level II, 88% for Level III, 60% for Level IV, and 15% for Level V melanoma. The presence of nodal metastases augured a much worse prognosis than Clark's level per se. In patients with Level IV melanoma, the 5-year cure rate was 82% in patients with negative nodes and 27% in those with nodal metastases after elective node dissection. Microstaging primary melanoma according to Clark's levels serves as a useful standard with which to compare surgical results. In this series of extremity melanomas there was no difference between local recurrence and lymphadenectomy for Level II melanoma. For Level III and Level IV melanoma, wide excision and lymphadenectomy gave higher cure rates than wide excision only, both at 5 and 9 years after surgery. The results were significant only for patients with Level III, however. Use of the measured depth of invasion added significant clinicopathologic information. The incidence of nodal metastases at elective node dissection was 5 to 9% for melanoma showing 0.6 to 2.0 mm of invasion, 22% for melanoma measuring 2.1 to 3.0 mm, and 39% for melanoma invading beyond 3.0 mm. The 5-year cure rate was 100% for melanoma measuring less than 1.0 mm, 83% for melanoma invading 1.1 to 2.0 mm, 58% for lesions measuring 2.1 to 3.0 mm, and 55% for melanoma invading over 3.0 mm. The microstage technique combining Clark's levels and the measured depth of invasion has an important use as a prognostic index and as a standard upon which to select treatment for primary melanoma of the extremities.
 ...
PMID:Malignant melanoma of the extremities: a clinicopathologic study using levels of invasion (microstage). 111 35

Four percent of 2,446 patients with malignant melanoma did not have a known site of primary origin. More than half were admitted with nodal disease only, and were treated with regional node dissections. Thirty-three percent of this group lived five years, and 22 percent lived ten years following treatment. One third were admitted with visceral metastases, many of which were amenable to surgery, and this group experienced a 5 percent five-year survival rate. Cutaneous dissemination carried a lethal prognosis. Recurrences following treatment tended toward the same region of the body as the original metastasis, and 50 percent of these recurrences occurred within six months of therapy. The sex ratio, age incidence, family history, and survival rates in these patients with unknown primary tumors are consistent with an unnoticed cutaneous lesion as the site of origin for the metastatic disease. It must be supposed that this lesion had undergone spontaneous regression.
 ...
PMID:Malignant melanoma: the patient with an unknown site of primary origin. 115 55


1 2 3 4 5 6 7 8 9 10 Next >>